NuProbe Announces $11 Million Series A Funding Round

Early-stage molecular diagnostics company NuProbe raised $11 million to continue development of its non-invasive blood test for the early detection of cancer and infectious diseases. The Series A funding was co-led by Sequoia China and Serica Partners, with additional investor WuXi AppTec Corporate Ventures.

Developed and licensed at Harvard University’s Wyss Institute for Biologically Inspired Engineering and Rice University, NuProbe’s probe-based technology is a molecular strategy to test for diverse disease signatures, including cancer. According to the company, its technology identifies variants in the early stages, which can improve detection and help guide treatment decisions that may increase patient survival.

The funds will be used to increase staffing in its offices in Cambridge, Massachusetts and China, and to continue technology development, clinical trials, and commercialization.